LifeVantage Corporation (NASDAQ: LFVN) reported fourth fiscal quarter 2026 results that missed analyst expectations, with adjusted earnings per share coming in at $0.11 versus a consensus estimate of $0.13. Revenue for the quarter ended June 30, 2026 was $42.4 million, falling short of the $45.9 million forecast.

The miss reflects a broader contraction in the company's performance, driven by declining order volumes and active account attrition across its primary geographies.

Financial Performance

Revenue for the quarter fell 23.1% year-over-year (YoY) to $42.4 million ($42.377 million precisely), missing the analyst consensus estimate of $45.9 million by approximately 7.8%. Net income per diluted share dropped to $0.10 from $0.15 in the prior period, while adjusted EPS of $0.11 missed the $0.13 estimate by 15.4%.

The company's full-year revenue declined 20.1% to $182.6 million. The Americas region saw a 23.2% revenue decline, while Asia/Pacific and Europe fell 6.9%.

Gross margins contracted slightly as product mix shifts and inventory obsolescence expenses weighed on profitability. Gross profit was 78.0% of revenue in the quarter, down from 79.9% previously. For the full year, gross margin stood at 77.6%, compared to 80.4% in FY25.

What the Numbers Show

A critical divergence exists between top-line growth and operating expense leverage. While commissions and incentives as a percentage of revenue improved (falling to 41.3% from 42.1% in Q4), selling, general, and administrative (SG&A) costs rose relative to sales. SG&A increased to 32.7% of revenue in the quarter from 33.9% previously, but for the full year, it expanded to 32.0% from 30.3%. This indicates that fixed cost structures are becoming less efficient as revenue volume declines, pressuring operating income which fell to $1.7 million in the quarter.

Operational Metrics

The revenue decline is underpinned by a sharp reduction in the company's direct selling network. Total active accounts dropped 21.2% to 104,000 from 132,000 a year ago.

• Active independent consultants fell 15.7% to 43,000.
• Active customers declined 24.7% to 61,000.

Management attributed these declines to downward pressure in order numbers from the active account base and lower average order sizes, citing broader macro-economic impacts and lower sales of the MindBody GLP-1 System compared to the prior year period. Despite these headwinds, subscription-based revenue remained strong, comprising over 75% of total revenue in Q4, and customer retention metrics improved year over year.

Balance Sheet and Liquidity

Despite the revenue headwinds, LifeVantage maintains a debt-free balance sheet. Cash and cash equivalents stood at $14.9 million as of June 30, 2026, down from $20.2 million a year earlier. The company generated $10.2 million in cash from operations during FY26.

During the fiscal year, the company repurchased approximately 336,000 common shares for $2.0 million. As of June 30, $58.5 million remains available under its $60 million share repurchase program approved in January. Additionally, the company announced a quarterly cash dividend of $0.05 per share, payable on September 15, 2026.

Capital expenditures totaled $3.6 million in FY26, up from $1.4 million in FY25, reflecting continued investment in technology infrastructure, including Shopify integration. Management anticipates FY27 capex to be slightly lower, in the range of $3 million to $3.5 million, before returning to historical levels of $2 million to $2.5 million once projects conclude.

Outlook

Due to the recent transition in the Chief Executive Officer role, the company did not issue formal guidance for fiscal 2027. New CEO Terrence Moorehead emphasized a focus on strengthening the brand, building consumer propositions, and driving operational excellence. He identified three priorities: strengthening the LifeVantage brand, building a more relevant consumer proposition, and improving operational excellence. The company also maintains access to a $5 million revolving credit line.

LifeVantage Corporation (NASDAQ: LFVN) will release its financial results for the fourth quarter and full fiscal year ended June 30, 2026, after the US stock market closes on Thursday, August 27, 2026.

The Salt Lake City-based health and wellness company, which markets products designed to activate cellular health processes, scheduled a conference call for investors at 2:30 pm Mountain Time (4:30 pm Eastern Time) on the same day.

Conference Call Details

Investors can participate in the live call by dialing (877) 704-4453 from the US or (201) 389-0920 for international callers. A telephone replay will be available approximately two hours after the call concludes and will remain accessible through Thursday, September 17, 2026.

Replay access details:

• US callers: Dial (844) 512-2921 with confirmation code 13761673
• International callers: Dial (412) 317-6671 with confirmation code 13761673

A simultaneous live webcast will be available on the Investor Relations section of the company’s website. The webcast will be archived for approximately 30 days.

About LifeVantage

LifeVantage describes itself as a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds can unlock genetic health potential. Its product line includes the flagship Protandim family of products, TrueScience Liquid Collagen, MindBody GLP-1 System, and P84 gut activator.

The company also offers activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System, alongside AXIO nootropic energy drink mixes, TrueScience skin and hair care products, and Petandim pet supplements.

Founded in 2003 and headquartered in Lehi, Utah, LifeVantage sells its products through independent consultants who share the business opportunity with entrepreneurs.